Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson's Disease

被引:45
|
作者
Oczkowska, Anna [1 ]
Kozubski, Wojciech [2 ]
Lianeri, Margarita [3 ]
Dorszewska, Jolanta [1 ]
机构
[1] Poznan Univ Med Sci, Dept Neurol, Neurobiol Lab, PL-60355 Poznan, Poland
[2] Poznan Univ Med Sci, Chair & Dept Neurol, PL-60355 Poznan, Poland
[3] Poznan Univ Med Sci, Dept Biochem & Mol Biol, PL-60355 Poznan, Poland
关键词
Alpha-synuclein; Parkin; Parkinson's disease; PRKN; SNCA; RECESSIVE JUVENILE PARKINSONISM; MUTANT ALPHA-SYNUCLEIN; PSEUDO-DOMINANT INHERITANCE; UBIQUITIN-PROTEIN LIGASE; TRANSGENIC MOUSE MODEL; SUBCELLULAR-LOCALIZATION; ASYMPTOMATIC CARRIERS; HOMOZYGOUS DELETIONS; ALZHEIMERS-DISEASE; MOLECULAR PATHWAYS;
D O I
10.2174/1389202914666131210205839
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although Parkinson's disease (PD) was first described almost 200 years ago, it remains an incurable disease with a cause that is not fully understood. Nowadays it is known that disturbances in the structure of pathological proteins in PD can be caused by more than environmental and genetic factors. Despite numerous debates and controversies in the literature about the role of mutations in the SNCA and PRKN genes in the pathogenesis of PD, it is evident that these genes play a key role in maintaining dopamine (DA) neuronal homeostasis and that the dysfunction of this homeostasis is relevant to both familial (FPD) and sporadic (SPD) PD with different onset. In recent years, the importance of alpha-synuclein (ASN) in the process of neurodegeneration and neuroprotective function of the Parkin is becoming better understood. Moreover, there have been an increasing number of recent reports indicating the importance of the interaction between these proteins and their encoding genes. Among others interactions, it is suggested that even heterozygous substitution in the PRKN gene in the presence of the variants +2/+2 or +2/+3 of NACP-Rep1 in the SNCA promoter, may increase the risk of PD manifestation, which is probably due to ineffective elimination of over-expressed ASN by the mutated Parkin protein. Finally, it seems that genetic testing may be an important part of diagnostics in patients with PD and may improve the prognostic process in the course of PD. However, only full knowledge of the mechanism of the interaction between the genes associated with the pathogenesis of PD is likely to help explain the currently unknown pathways of selective damage to dopaminergic neurons in the course of PD.
引用
收藏
页码:502 / 517
页数:16
相关论文
共 50 条
  • [1] Diagnostic delay in Parkinson's disease caused by PRKN mutations
    Ruiz-Lopez, Marta
    Freitas, Maria Eliza
    Oliveira, Lais M.
    Munhoz, Renato P.
    Fox, Susan H.
    Rohani, Mohammad
    Rogaeva, Ekaterina
    Lang, Anthony E.
    Fasano, Alfonso
    PARKINSONISM & RELATED DISORDERS, 2019, 63 : 217 - 220
  • [2] Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2
    Bras, Jose
    Guerreiro, Rita
    Ribeiro, Maria
    Morgadinho, Ana
    Januario, Cristina
    Dias, Margarida
    Calado, Ana
    Semedo, Cristina
    Oliveira, Catarina
    Hardy, John
    Singleton, Andrew
    BMC NEUROLOGY, 2008, 8 (1)
  • [3] Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2
    Jose Bras
    Rita Guerreiro
    Maria Ribeiro
    Ana Morgadinho
    Cristina Januario
    Margarida Dias
    Ana Calado
    Cristina Semedo
    Catarina Oliveira
    John Hardy
    Andrew Singleton
    BMC Neurology, 8
  • [4] The SNCA gene two novel missense mutations in Parkinson's disease
    Koziorowski, D.
    Jurek, M.
    Poznanski, J.
    Hoffman-Zacharska, D.
    Friedman, A.
    MOVEMENT DISORDERS, 2012, 27 : S460 - S460
  • [5] Heterozygous PRKN mutations are common but do not increase the risk of Parkinson's disease
    Zhu, William
    Huang, Xiaoping
    Yoon, Esther
    Bandres-Ciga, Sara
    Blauwendraat, Cornelis
    Billingsley, Kimberly J.
    Cade, Joshua H.
    Wu, Beverly P.
    Williams, Victoria H.
    Schindler, Alice B.
    Brooks, Janet
    Gibbs, J. Raphael
    Hernandez, Dena G.
    Ehrlich, Debra
    Singleton, Andrew B.
    Narendra, Derek P.
    BRAIN, 2022, 145 (06) : 2077 - 2091
  • [6] Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson's Disease Treatment
    Bispo, Ana Gabrielle
    Silva, Caio S.
    Sena-dos-Santos, Camille
    Moura, Dafne Dalledone
    Koshimoto, Brenda Hanae Bentes
    Santos-Lobato, Bruno Lopes
    Ribeiro-dos-Santos, Andrea
    Cavalcante, Giovanna C.
    BIOMEDICINES, 2023, 11 (08)
  • [7] Genetic variability in SNCA and Parkinson's disease
    Pihlstrom, Lasse
    Toft, Mathias
    NEUROGENETICS, 2011, 12 (04) : 283 - 293
  • [8] Genetic variability in SNCA and Parkinson’s disease
    Lasse Pihlstrøm
    Mathias Toft
    neurogenetics, 2011, 12 : 283 - 293
  • [9] Assessing the relationship between monoallelic PRKN mutations and Parkinson's risk
    Lubbe, Steven J.
    Bustos, Bernabe, I
    Hu, Jing
    Krainc, Dimitri
    Joseph, Theresita
    Hehir, Jason
    Tan, Manuela
    Zhang, Weijia
    Escott-Price, Valentina
    Williams, Nigel M.
    Blauwendraat, Cornelis
    Singleton, Andrew B.
    Morris, Huw R.
    HUMAN MOLECULAR GENETICS, 2021, 30 (01) : 78 - 86
  • [10] APOE, MAPT, and SNCA Genes and Cognitive Performance in Parkinson Disease
    Mata, Ignacio F.
    Leverenz, James B.
    Weintraub, Daniel
    Trojanowski, John Q.
    Hurtig, Howard I.
    Van Deerlin, Vivianna M.
    Ritz, Beate
    Rausch, Rebecca
    Rhodes, Shannon L.
    Factor, Stewart A.
    Wood-Siverio, Cathy
    Quinn, Joseph F.
    Chung, Kathryn A.
    Peterson, Amie L.
    Espay, Alberto J.
    Revilla, Fredy J.
    Devoto, Johnna
    Hu, Shu-Ching
    Cholerton, Brenna A.
    Wan, Jia Y.
    Montine, Thomas J.
    Edwards, Karen L.
    Zabetian, Cyrus P.
    JAMA NEUROLOGY, 2014, 71 (11) : 1405 - 1412